Phylogica (Germany) Today
| PH7 Stock | EUR 0.62 0.00 0.00% |
Performance9 of 100
| Odds Of DistressOver 57
|
Phylogica is selling for under 0.62 as of the 14th of December 2024; that is No Change since the beginning of the trading day. The stock's last reported lowest price was 0.62. Phylogica has over 57 % chance of experiencing financial distress in the next 2 years of operation and did not have a very good performance during the last 90 trading days. Phylogica has reported 10 for 1 split on 15th of November 2024. The performance scores are derived for the period starting the 15th of September 2024 and ending today, the 14th of December 2024. Click here to learn more.
Moving against Phylogica Stock
Phylogica Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Phylogica's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Phylogica or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| Business Concentration | Biotechnology, Healthcare (View all Sectors) |
Phylogica Limited (PH7) is traded on Munich Exchange in Germany and employs 7 people. The company currently falls under 'Small-Cap' category with a current market capitalization of 284.31 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Phylogica's market, we take the total number of its shares issued and multiply it by Phylogica's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Phylogica Limited operates under Healthcare sector and is part of Biotechnology industry. The entity has 3.18 B outstanding shares.
Check Phylogica Probability Of Bankruptcy
Ownership AllocationPhylogica owns a total of 3.18 Billion outstanding shares. Phylogica has significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Phylogica Ownership Details
Phylogica Limited Risk Profiles
Although Phylogica's alpha and beta are two of the key measurements used to evaluate Phylogica's performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 27.0 | |||
| Standard Deviation | 111.38 | |||
| Variance | 12405.69 | |||
| Risk Adjusted Performance | 0.0992 |
Phylogica Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Phylogica without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Stock Screener Now
Stock ScreenerFind equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. |
| All Next | Launch Module |
Phylogica Corporate Management
Elected by the shareholders, the Phylogica's board of directors comprises two types of representatives: Phylogica inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Phylogica. The board's role is to monitor Phylogica's management team and ensure that shareholders' interests are well served. Phylogica's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Phylogica's outside directors are responsible for providing unbiased perspectives on the board's policies.
| MD MBA | Chief Operations | Profile | |
| Glenn Noronha | Chief Officer | Profile | |
| BComm BCom | Company CFO | Profile | |
| Kaggen LLB | Chief Officer | Profile | |
| MBA MBA | CEO operations | Profile | |
| Pr Fletcher | Chief Officer | Profile | |
| GDLP JD | CEO Director | Profile |
Additional Tools for Phylogica Stock Analysis
When running Phylogica's price analysis, check to measure Phylogica's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Phylogica is operating at the current time. Most of Phylogica's value examination focuses on studying past and present price action to predict the probability of Phylogica's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Phylogica's price. Additionally, you may evaluate how the addition of Phylogica to your portfolios can decrease your overall portfolio volatility.